Table 5 Group factor effect
| Â | Estimated marginal means | p values | ||||
|---|---|---|---|---|---|---|
|  | Group 1 (MTX) | Group 2 (ADA + MTX) | Group 3 (Control) | Gr. 1 vs. 2 | Gr. 1 vs. 3 | Gr. 2 vs. 3 |
Subpopulation | Mean ± SD and 95% CI | |||||
CD3+ (abs.) | 1589.0 ± 832.9 1325.0-1852.0 | 2044.0 ± 851.3 1846.0-2242.0 | 1622.0 ± 834.9 1405.0-1839.0 | 0.023 | 1.000 | 0.017 |
CD3/CD25+ (%) | 10.2 ± 5.35 8.49–11.8 | 10.3 ± 5.44 9.02–11.6 | 10.5 ± 5.31 9.08–11.8 | 1.000 | 1.000 | 1.000 |
CD3/CD45RA (%) | 44.2 ± 17.03 38.9–49.6 | 43.1 ± 17.29 39.1–47.1 | 40.4 ± 16.9 36.0-44.8 | 1.000 | 0.824 | 1.000 |
CD3/CD45RO (%) | 30.9 ± 14.66 26.3–35.4 | 32.4 ± 14.88 28.9–35.9 | 30.8 ± 14.59 27.0-34.6 | 1.000 | 1.000 | 1.000 |
CD4+ (abs.) | 906.0 ± 451.57 763.0-1049.0 | 1119.0 ± 461.94 1012.0-1227.0 | 926.0 ± 452.42 809.0-1044.0 | 0.060 | 1.000 | 0.056 |
CD8+ (abs.) | 582.0 ± 435.13 444.0-719.0 | 770.0 ± 445.60 667.0-874.0 | 582.0 ± 436.29 468.0-695.0 | 0.098 | 1.000 | 0.050 |
CD19+ (abs.) | 210.0 ± 204.28 145.0-274.0 | 288.0 ± 206.46 239.0-336.0 | 261.0 ± 204.32 208.0-314.0 | 0.174 | 0.672 | 1.000 |
Lymphocyte (abs.) | 2120 ± 1040 1800–2440 | 2700 ± 1050 2450–2940 | 2260 ± 1030 1990–2520 | 0.016 | 1.000 | 0.052 |
Naive B (%) | 78.7 ± 14.82 74.2–83.3 | 77.8 ± 14.8 74.4–81.3 | 78.7 ± 14.52 74.9–82.5 | 1.000 | 1.000 | 1.000 |
NK cell (%) | 11.9 ± 8.21 9.43–14.4 | 10.3 ± 8.22 8.44–12.2 | 14.4 ± 8.09 12.28–16.50 | 0.936 | 0.425 | 0.018 |
NKT cell (%) | 7.02 ± 8.50 4.41–9.63 | 4.63 ± 8.40 2.64–6.62 | 5.43 ± 8.40 3.25–7.61 | 0.445 | 1.000 | 1.000 |
Switched B (%) | 12.7 ± 9.97 9.65–15.7 | 12.8 ± 9.98 10.49–15.1 | 13.4 ± 9.83 10.84-16.0 | 1.000 | 1.000 | 1.000 |